dc.contributor.author |
Ghazzal Z.B. |
dc.contributor.author |
Dhawan S.S. |
dc.contributor.author |
Sheikh A. |
dc.contributor.author |
Douglas J.S. |
dc.contributor.author |
Veledar E. |
dc.contributor.author |
Mavromatis K. |
dc.contributor.author |
Pohlel F.K. |
dc.contributor.author |
Vaccarino V. |
dc.contributor.editor |
|
dc.date |
Apr-2009 |
dc.date.accessioned |
2017-10-05T15:39:20Z |
dc.date.available |
2017-10-05T15:39:20Z |
dc.date.issued |
2009 |
dc.identifier |
10.1016/j.amjcard.2008.11.053 |
dc.identifier.isbn |
|
dc.identifier.issn |
00029149 |
dc.identifier.uri |
http://hdl.handle.net/10938/16808 |
dc.description.abstract |
Low levels of high-density lipoprotein (HDL) cholesterol are a marker of coronary artery disease progression and are associated with cardiovascular events. However, whether low HDL cholesterol is a useful prognostic indicator after percutaneous coronary intervention (PCI) is not known. In a sample of 4,088 patients who underwent PCI we evaluated 1-year mortality and repeat revascularization as a function of baseline HDL levels classified into approximate quartiles of very low (35 mg-dl), low (35 to 40 mg-dl), medium (41 to 47 mg-dl) and high (48 to 120 mg-dl) HDL cholesterol. Decreasing levels of HDL cholesterol were associated with younger age, male gender, smoking, diabetes mellitus, and a history of bypass surgery (p 0.0001 for all). One-year mortality and coronary revascularization were significantly higher in the very low HDL cholesterol group compared with the other groups (very low HDL cholesterol 6.5percent and 25.4percent, respectively; low HDL cholesterol 3.1percent and 20.8percent; medium HDL cholesterol 4.3percent and 22.7percent; high HDL cholesterol 3.1percent and 20.6percent, p = 0.0001 and p = 0.007). One-year mortality was significantly higher in men with an HDL cholesterol level 33 mg-dL and in women with an HDL cholesterol level 38 mg-dL. In multivariable analysis, very low HDL was associated with nearly twofold the risk of death after adjusting for other independent predictors of outcome. In conclusion, in patients with coronary artery disease undergoing PCI, a baseline HDL cholesterol level 35mg-dl is an important prognostic indicator. Baseline HDL cholesterol levels 33 mg-dl for men and 38 mg-dl were associated with higher one-year mortality after PCI. © 2009 Elsevier Inc. All rights reserved. |
dc.format.extent |
|
dc.format.extent |
Pages: (902-906) |
dc.language |
English |
dc.publisher |
BRIDGEWATER |
dc.relation.ispartof |
Publication Name: American Journal of Cardiology; Publication Year: 2009; Volume: 103; no. 7; Pages: (902-906); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Usefulness of Serum High-Density Lipoprotein Cholesterol Level as an Independent Predictor of One-Year Mortality After Percutaneous Coronary Interventions |
dc.type |
Article |
dc.contributor.affiliation |
Ghazzal, Z.B., Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States, American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation |
Dhawan, S.S., Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States |
dc.contributor.affiliation |
Sheikh, A., Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States |
dc.contributor.affiliation |
Douglas, J.S., Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States |
dc.contributor.affiliation |
Veledar, E., Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States |
dc.contributor.affiliation |
Mavromatis, K., Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States |
dc.contributor.affiliation |
Pohlel, F.K., Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States |
dc.contributor.affiliation |
Vaccarino, V., Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States, Rollins School of Public Health, Emory University, Atlanta, GA, United States |
dc.contributor.authorAddress |
Ghazzal, Z.B.; Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States; email: ziyad.ghazzal@emoryhealthcare.org |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; |
dc.contributor.authorDepartment |
Internal Medicine |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
ziyad.ghazzal@emoryhealthcare.org |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
Ghazzal, ZB |
dc.contributor.authorInitials |
Dhawan, SS |
dc.contributor.authorInitials |
Sheikh, A |
dc.contributor.authorInitials |
Douglas, JS |
dc.contributor.authorInitials |
Veledar, E |
dc.contributor.authorInitials |
Mavromatis, K |
dc.contributor.authorInitials |
Khan-Pohlel, F |
dc.contributor.authorInitials |
Vaccarino, V |
dc.contributor.authorOrcidID |
Veledar, Emir-0000-0002-3831-5433 |
dc.contributor.authorReprintAddress |
Ghazzal, ZB (reprint author), Emory Univ, Div Cardiol, Dept Med, Sch Med, Atlanta, GA 30322 USA. |
dc.contributor.authorResearcherID |
Veledar, Emir-K-2808-2012 |
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
Barter P, 2007, NEW ENGL J MED, V357, P1301, DOI 10.1056-NEJMoa064278; CASTELLI WP, 1977, CIRCULATION, V55, P767; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001-jama.256.20.2835; Cole JH, 2003, J AM COLL CARDIOL, V41, P521, DOI 10.1016-S0735-1097(03)02862-0; Cui YD, 2001, ARCH INTERN MED, V161, P1413, DOI 10.1001-archinte.161.11.1413; Goldenberg I, 2006, AM J CARDIOL, V97, P466, DOI 10.1016-j.amjcard.2005.09.078; GORDON DJ, 1989, CIRCULATION, V79, P8; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016-0002-9343(77)90874-9; Grant RW, 2007, DIABETES CARE, V30, P479, DOI 10.2337-dc06-1961; Haffner Steven M, 2004, Diabetes Care, V27 Suppl 1, pS68; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32; Lundstam U, 2002, J INTERN MED, V251, P111, DOI 10.1046-j.1365-2796.2002.00937.x; Okamura T, 2006, ATHEROSCLEROSIS, V184, P143, DOI 10.1016-j.atherosclerosis.2005.03.042; Olsson AG, 2005, EUR HEART J, V26, P890, DOI 10.1093-eurheartj-ehi186; THOMPSON P, 1978, J AM GERIATR SOC, V26, P440; Weintraub WS, 2003, CIRCULATION, V107, P1271, DOI 10.1161-01.CIR.0000053642.34528.D9 |
dc.description.citedCount |
13 |
dc.description.citedTotWOSCount |
11 |
dc.description.citedWOSCount |
10 |
dc.format.extentCount |
5 |
dc.identifier.articleNo |
|
dc.identifier.coden |
AJCDA |
dc.identifier.pubmedID |
19327413 |
dc.identifier.scopusID |
62849086187 |
dc.identifier.url |
|
dc.publisher.address |
685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Am. J. Cardiol. |
dc.relation.ispartOfIssue |
7 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
American Journal of Cardiology |
dc.relation.ispartofPubTitleAbbr |
Am. J. Cardiol. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
103 |
dc.source.ID |
WOS:000264819000002 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
|
dc.subject.otherChemCAS |
Biological Markers |
dc.subject.otherChemCAS |
Cholesterol, HDL |
dc.subject.otherIndex |
high density lipoprotein cholesterol |
dc.subject.otherIndex |
adult |
dc.subject.otherIndex |
age |
dc.subject.otherIndex |
aged |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
bypass surgery |
dc.subject.otherIndex |
cholesterol blood level |
dc.subject.otherIndex |
death |
dc.subject.otherIndex |
diabetes mellitus |
dc.subject.otherIndex |
female |
dc.subject.otherIndex |
gender |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
major clinical study |
dc.subject.otherIndex |
male |
dc.subject.otherIndex |
mortality |
dc.subject.otherIndex |
outcome assessment |
dc.subject.otherIndex |
percutaneous coronary intervention |
dc.subject.otherIndex |
prediction |
dc.subject.otherIndex |
priority journal |
dc.subject.otherIndex |
prognosis |
dc.subject.otherIndex |
risk assessment |
dc.subject.otherIndex |
risk factor |
dc.subject.otherIndex |
sex difference |
dc.subject.otherIndex |
smoking |
dc.subject.otherIndex |
Aged |
dc.subject.otherIndex |
Angioplasty, Transluminal, Percutaneous Coronary |
dc.subject.otherIndex |
Biological Markers |
dc.subject.otherIndex |
Cholesterol, HDL |
dc.subject.otherIndex |
Female |
dc.subject.otherIndex |
Follow-Up Studies |
dc.subject.otherIndex |
Georgia |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Male |
dc.subject.otherIndex |
Middle Aged |
dc.subject.otherIndex |
Myocardial Ischemia |
dc.subject.otherIndex |
Prognosis |
dc.subject.otherIndex |
Prospective Studies |
dc.subject.otherIndex |
Recurrence |
dc.subject.otherIndex |
Risk Factors |
dc.subject.otherIndex |
Sex Factors |
dc.subject.otherIndex |
Survival Rate |
dc.subject.otherKeywordPlus |
CARDIOVASCULAR-DISEASE MORTALITY |
dc.subject.otherKeywordPlus |
HEART-DISEASE |
dc.subject.otherKeywordPlus |
HDL CHOLESTEROL |
dc.subject.otherKeywordPlus |
FOLLOW-UP |
dc.subject.otherKeywordPlus |
PREVALENCE |
dc.subject.otherKeywordPlus |
FRAMINGHAM |
dc.subject.otherKeywordPlus |
LIPIDS |
dc.subject.otherKeywordPlus |
TRIAL |
dc.subject.otherWOS |
Cardiac and Cardiovascular Systems |